EUVIMEDEUVIMED entdecken
Crossref

Noncanonical MAVS signaling restrains dendritic cell–driven antitumor immunity by inhibiting IL-12

Lingling Wu iD, Xiaochuan Hong iD, Chao Yang iD, Yuanqin Yang iD, Wenwen Li iD, Lu Lu iD, Meichun Cai, Dongqing Cao iD, Guanglei Zhuang iD, Liufu Deng iD

Science Immunology · 22.12.2023 · 8 (90)

DOI: 10.1126/sciimmunol.adf4919 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Immunology, erschienen am 22.12.2023. Verfasst von Lingling Wu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Immunology, Department of Immunology and Microbiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry…. Hauptthemen laut MEDLINE: Interleukin-12, Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mitochondrial antiviral signaling protein (MAVS)–mediated cytosolic RNA sensing plays a central role in tumor immunogenicity. However, the effects of host MAVS signaling on antitumor immunity remain unclear. Here, we demonstrate that the host MAVS pathway supports tumor growth and impairs antitumor immunity, whereas MAVS deficiency in dendritic cells (DCs) promotes tumor-reactive CD8 + T cell responses. Specifically, CD8 + T cell priming capacity was enhanced by MAVS ablation in a type I interferon–independent, but IL-12–dependent, manner. Mechanistically, loss of the RIG-I/MAVS cascade activated the noncanonical NF-κB pathway and in turn induced IL-12 production by DCs. MAVS-restrained IL-12 promoted cross-talk between CD8 + T cells and DCs, which was licensed by IFN-γ. Moreover, ablation of host MAVS sensitized tumors to immunotherapy and attenuated radiation resistance, thereby facilitating the maintenance of effector CD8 + T cells. These findings demonstrate that the host MAVS pathway acts as an immune regulator of DC-driven antitumor immunity and support the development of immunotherapies that antagonize MAVS signaling in DCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Interleukin-12NeoplasmsHumansCD8-Positive T-LymphocytesSignal TransductionDendritic Cells

Substanzen

Interleukin-12

Autor:innen und Institutionen

  • Shanghai Institute of Immunology, Department of Immunology and Microbiology, Key Laboratory of Cell Differentiation and Apoptosis of Chinese Ministry of Education, Shanghai Jiao Tong University School of Medicine, Shang…
  • Shanghai Frontiers Science Center of Drug Target Identification and Delivery, National Key Laboratory of Innovative Immunotherapy, School of Pharmacy, Shanghai Jiao Tong University, Shanghai 200240, China.
  • Shanghai Key Laboratory of Gynecologic Oncology, Shanghai Cancer Institute, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine, 200217, Shanghai, China.
  • Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

ORCID-Profile: Lingling Wu, Xiaochuan Hong, Chao Yang, Yuanqin Yang, Wenwen Li, Lu Lu, Dongqing Cao, Guanglei Zhuang, Liufu Deng

Zitieren

APA

Wu, L., Hong, X., Yang, C., Yang, Y., Li, W., Lu, L., Cai, M., Cao, D., Zhuang, G., & Deng, L. (2023). Noncanonical MAVS signaling restrains dendritic cell–driven antitumor immunity by inhibiting IL-12. Science Immunology, 8(90). https://doi.org/10.1126/sciimmunol.adf4919

Vancouver

Wu L, Hong X, Yang C, Yang Y, Li W, Lu L, et al. Noncanonical MAVS signaling restrains dendritic cell–driven antitumor immunity by inhibiting IL-12. Science Immunology. 2023;8(90). doi:10.1126/sciimmunol.adf4919

BibTeX
@article{Wu2023,
  author = {Wu, Lingling and Hong, Xiaochuan and Yang, Chao and Yang, Yuanqin and Li, Wenwen and Lu, Lu and Cai, Meichun and Cao, Dongqing and Zhuang, Guanglei and Deng, Liufu},
  title = {Noncanonical MAVS signaling restrains dendritic cell–driven antitumor immunity by inhibiting IL-12},
  journal = {Science Immunology},
  year = {2023},
  volume = {8},
  number = {90},
  doi = {10.1126/sciimmunol.adf4919}
}
Kostenlos starten →